inclusion criteria: age 18 to 65 years of age able to provide informed consent able and willing to comply with study procedures and agree to refrain from obtaining a booster vaccination with a non-study vaccine through to the 1 month post-boost vaccination visit for women of childbearing potential, able and willing to use an approved form of pregnancy prevention for at least 4 weeks from study drug administration completion of a prior vaccination series with either the bnt162b2, mrna-1273, or ad26.cov.s vaccines, with or without subsequent booster vaccination, with most recent vaccination at least 6 months prior to study entry

inclusion criteria: age 18 to 65 years of age able to provide informed consent able and willing to comply with study procedures and agree to refrain from obtaining a booster vaccination with a non-study vaccine through to the 1 month post-boost vaccination visit for women of childbearing potential, able and willing to use an approved form of pregnancy prevention for at least 4 weeks from study drug administration completion of a prior vaccination series with either the bnt162b2, mrna-1273, or ad26.cov.s vaccines, with or without subsequent booster vaccination, with most recent vaccination at least 6 months prior to study entry

inclusion criteria: age 18 to 65 years of age able to provide informed consent able and willing to comply with study procedures and agree to refrain from obtaining a booster vaccination with a non-study vaccine through to the 1 month post-boost vaccination visit for women of childbearing potential, able and willing to use an approved form of pregnancy prevention for at least 4 weeks from study drug administration completion of a prior vaccination series with either the bnt162b2, mrna-1273, or ad26.cov.s vaccines at least 6 months prior to study entry

inclusion criteria: age 18 to 65 years of age able to provide informed consent able and willing to comply with study procedures and agree to refrain from obtaining a booster vaccination with a non-study vaccine through to the 1 month post-boost vaccination visit for women of childbearing potential, able and willing to use an approved form of pregnancy prevention for at least 4 weeks from study drug administration completion of a prior vaccination series with either the bnt162b2, mrna-1273, or ad26.cov.s vaccines at least 6 months prior to study entry